Nuformix (NFX) News Today → I’m afraid WWIII is a very real possibility (From Porter & Company) (Ad) Free NFX Stock Alerts GBX 0.18 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsStock AnalysisChartCompetitors All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative November 16, 2023 | morningstar.comNuformix PLC NFXOctober 23, 2023 | lse.co.ukNuformix gets patent in Japan for pulmonary fibrosis treatment NXP002October 5, 2023 | finance.yahoo.comNuformix to fund its unlicensed programs with NXP001 windfallJuly 25, 2023 | uk.investing.comCloud Village Inc (9899)July 15, 2023 | uk.investing.comK Seng Seng Corporation Bhd (KSSC)July 14, 2023 | uk.investing.comSuzumo Machinery Co Ltd (6405)July 13, 2023 | uk.investing.comENGAGE XR Holdings PLC (EXRE)April 17, 2023 | lse.co.ukNuformix raises GBP70,000 to fund NXP002 programmeApril 17, 2023 | marketwatch.comNuformix Raises GBP70,000 in Discount Share SubscriptionMarch 27, 2023 | marketwatch.comNuformix Says Study Shows Effectiveness of New Lung-Disease Treatment CandidateMarch 13, 2023 | marketwatch.comNuformix to Change Financial Year End to Sept. 30December 20, 2022 | marketwatch.comNuformix Shares Rise on Positive Olaparib Cancer Treatment Study ResultsDecember 20, 2022 | proactiveinvestors.com.auNuformix delighted as NXP004 testing exceeds its expectationsDecember 13, 2022 | lse.co.ukNuformix interim loss virtually flat as continues work on drugsSeptember 23, 2022 | marketwatch.comNuformix to Start New NXP002 Study Program; Cancels Current Human IPF Tissue StudySeptember 17, 2022 | lse.co.ukLONDON MARKET EARLY CALL: Soft end to rocky week; UK retail sales dueAugust 10, 2022 | marketwatch.comNuformix Shares Rise on Completion of Pre-Clinical Tolerability Studies for NXP002 TreatmentJuly 28, 2022 | marketwatch.comNuformix 1H Pretax Loss Narrowed on Lower Costs; Shares RiseJune 27, 2022 | marketwatch.comNuformix to Continue Investigating NXP002 TreatmentMay 31, 2022 | lse.co.ukNuformix Executive Chair Alastair Riddell resigns after one yearMay 31, 2022 | ca.proactiveinvestors.comNuformix chairman resigns to take up new roleMay 30, 2022 | marketwatch.comNuformix Shares Drop After NXP002 Trial Results Were Inconsistent, Failure to Identify New ChiefMay 30, 2022 | ca.proactiveinvestors.comNuformix updates on NXP002, drug pipeline and CEO searchApril 12, 2022 | proactiveinvestors.comNuformix will receive a gross £1.32mln from second tranche of Lanstead funding agreementApril 5, 2022 | marketwatch.comNuformix Shareholder Raises Stake to 16.6%December 14, 2021 | marketwatch.comNuformix Investor Subscription to Raise GBP1.7 Mln for Product DevelopmentDecember 14, 2021 | marketwatch.comNuformix 1H Loss Narrowed Slightly on Lower CostsNovember 25, 2021 | marketwatch.comNuformix Shares Rise on Positive Trial StudiesNovember 12, 2021 | marketwatch.comNuformix Files New Patent Application for Cancer TreatmentNovember 9, 2021 | lse.co.ukCORRECT: Nuformix Chair Alastair Riddell to move to executive chairOctober 21, 2021 | lse.co.ukChill Brands Share ChatSeptember 14, 2021 | lse.co.ukLONDON BRIEFING: AB Foods says Primark sales growth hit by 'pingdemic'September 13, 2021 | marketwatch.comNuformix Shares Rise on Global Agreement for Cancer-Drug LicenseJuly 23, 2021 | proactiveinvestors.comNo knee jerk reaction from Nuformix over CEO resignationJuly 22, 2021 | lse.co.ukEXECUTIVE CHANGES: Nuformix responds to "frustration" as CEO departs Get Nuformix News Delivered to You Automatically Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter. Email Address I’m afraid WWIII is a very real possibility (Ad)As one top U.S. cyber official claims: This [tech] is “the most powerful weapon of our time.” That's also why I've produced this new film. Take a look. NFX Media Mentions By Week NFX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NFX News Sentiment▼0.000.51▲Average Medical News Sentiment NFX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NFX Articles This Week▼00▲NFX Articles Average Week Get Nuformix News Delivered to You Automatically Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PYC News RENE News FAB News EVG News OCTP News IXI News VAL News ROQ News IQAI News SUN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:NFX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMost important medical advance in 100 yearsThe Oxford ClubThe Presidential candidate you should REALLY be worried aboutStansberry ResearchMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuformix plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.